This Article  • Full text  • PDF  • eFigure  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Pain  • Patient-Physician Relationship/ Care  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Paul Yih Seng Chua, MBChB; Izabela Mitrut, MD; Ana-Marie Armbrecht, PhD; Archana Vani, MRCOphth; Tariq Aslam, MD; Baljean Dhillon, FRCS, FRCOphth

Arch Ophthalmol. 2009;127(7):939-940.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Ranibizumab (Lucentis) intravitreous injection (IVI) has emerged as a common treatment for wet age-related macular degeneration after 2 international, multicenter, controlled clinical trials, MARINA¹ and ANCHOR,² reported positive visual outcome compared with placebo and photodynamic therapy. Despite the therapeutic benefits of ranibizumab, repeated injections are required as often as every 4 weeks. We aimed to study the patients' perspective of treatment with ranibizumab, specifically pain, anxiety, and discomfort related to the ranibizumab IVI procedure. To our knowledge, there are no reports on this apart from one study investigating patient discomfort on receiving triamcinolone IVI.³

Methods

A validated questionnaire (eFigure) that covered the levels of discomfort, anxiety, and fear was administered to all of the patients 1 hour before the IVI at the preassessment clinic. The postoperative questionnaire was . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?